FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308365855> ?p ?o ?g. }

• W4308365855 endingPage "1745" @default.
• W4308365855 startingPage "1735" @default.
• W4308365855 abstract "Background: There are no randomized data evaluating the safety or efficacy of apixaban for stroke prevention in patients with end-stage kidney disease on hemodialysis and with atrial fibrillation (AF). Methods: The RENAL-AF trial (Renal Hemodialysis Patients Allocated Apixaban Versus Warfarin in Atrial Fibrillation) was a prospective, randomized, open-label, blinded-outcome evaluation (PROBE) of apixaban versus warfarin in patients receiving hemodialysis with AF and a CHA 2 DS 2 -VASc score ≥2. Patients were randomly assigned 1:1 to 5 mg of apixaban twice daily (2.5 mg twice daily for patients ≥80 years of age, weight ≤60 kg, or both) or dose-adjusted warfarin. The primary outcome was time to major or clinically relevant nonmajor bleeding. Secondary outcomes included stroke, mortality, and apixaban pharmacokinetics. Pharmacokinetic sampling was day 1, day 3, and month 1. Results: From January 2017 through January 2019, 154 patients were randomly assigned to apixaban (n=82) or warfarin (n=72). The trial stopped prematurely because of enrollment challenges. Time in therapeutic range (international normalized ratio, 2.0–3.0) for warfarin-treated patients was 44% (interquartile range, 23%–59%). The 1-year rates for major or clinically relevant nonmajor bleeding were 32% and 26% in apixaban and warfarin groups, respectively (hazard ratio, 1.20 [95% CI, 0.63–2.30]), whereas 1-year rates for stroke or systemic embolism were 3.0% and 3.3% in apixaban and warfarin groups, respectively. Death was the most common major event in the apixaban (21 patients [26%]) and warfarin (13 patients [18%]) arms. The pharmacokinetic substudy enrolled the target 50 patients. Median steady-state 12-hour area under the curve was 2475 ng/mL×h (10th to 90th percentiles, 1342–3285) for 5 mg of apixaban twice daily and 1269 ng/mL×h (10th to 90th percentiles, 615–1946) for 2.5 mg of apixaban twice daily. There was substantial overlap between minimum apixaban blood concentration, 12-hour area under the curve, and maximum apixaban blood concentration for patients with and without a major or clinically relevant nonmajor bleeding event. Conclusions: There was inadequate power to draw any conclusion regarding rates of major or clinically relevant nonmajor bleeding comparing apixaban and warfarin in patients with AF and end-stage kidney disease on hemodialysis. Clinically relevant bleeding events were ≈10-fold more frequent than stroke or systemic embolism among this population on anticoagulation, highlighting the need for future randomized studies evaluating the risks versus benefits of anticoagulation among patients with AF and end-stage kidney disease on hemodialysis. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02942407." @default.
• W4308365855 created "2022-11-11" @default.
• W4308365855 creator A5004084400 @default.
• W4308365855 creator A5005993471 @default.
• W4308365855 creator A5007315659 @default.
• W4308365855 creator A5012148455 @default.
• W4308365855 creator A5014449865 @default.
• W4308365855 creator A5014965271 @default.
• W4308365855 creator A5023508111 @default.
• W4308365855 creator A5033614042 @default.
• W4308365855 creator A5033776705 @default.
• W4308365855 creator A5039432822 @default.
• W4308365855 creator A5041339585 @default.
• W4308365855 creator A5046030309 @default.
• W4308365855 creator A5050920163 @default.
• W4308365855 creator A5060181316 @default.
• W4308365855 creator A5067237537 @default.
• W4308365855 creator A5070387023 @default.
• W4308365855 creator A5071880870 @default.
• W4308365855 creator A5071917576 @default.
• W4308365855 creator A5074500725 @default.
• W4308365855 creator A5081775695 @default.
• W4308365855 creator A5085683611 @default.
• W4308365855 date "2022-12-06" @default.
• W4308365855 modified "2023-10-17" @default.
• W4308365855 title "Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial" @default.
• W4308365855 cites W1586488555 @default.
• W4308365855 cites W1913544684 @default.
• W4308365855 cites W1981440884 @default.
• W4308365855 cites W1999468381 @default.
• W4308365855 cites W2025282593 @default.
• W4308365855 cites W2054077136 @default.
• W4308365855 cites W2054823150 @default.
• W4308365855 cites W2071729047 @default.
• W4308365855 cites W2099207046 @default.
• W4308365855 cites W2116559262 @default.
• W4308365855 cites W2124601103 @default.
• W4308365855 cites W2134119519 @default.
• W4308365855 cites W2137138584 @default.
• W4308365855 cites W2157689025 @default.
• W4308365855 cites W2162508946 @default.
• W4308365855 cites W2167698566 @default.
• W4308365855 cites W2556907923 @default.
• W4308365855 cites W2596305759 @default.
• W4308365855 cites W2897495391 @default.
• W4308365855 cites W2946652117 @default.
• W4308365855 cites W3000257998 @default.
• W4308365855 cites W3010912139 @default.
• W4308365855 cites W3011312705 @default.
• W4308365855 cites W3014494431 @default.
• W4308365855 cites W3139113952 @default.
• W4308365855 doi "https://doi.org/10.1161/circulationaha.121.054990" @default.
• W4308365855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36335914" @default.
• W4308365855 hasPublicationYear "2022" @default.
• W4308365855 type Work @default.
• W4308365855 citedByCount "34" @default.
• W4308365855 countsByYear W43083658552022 @default.
• W4308365855 countsByYear W43083658552023 @default.
• W4308365855 crossrefType "journal-article" @default.
• W4308365855 hasAuthorship W4308365855A5004084400 @default.
• W4308365855 hasAuthorship W4308365855A5005993471 @default.
• W4308365855 hasAuthorship W4308365855A5007315659 @default.
• W4308365855 hasAuthorship W4308365855A5012148455 @default.
• W4308365855 hasAuthorship W4308365855A5014449865 @default.
• W4308365855 hasAuthorship W4308365855A5014965271 @default.
• W4308365855 hasAuthorship W4308365855A5023508111 @default.
• W4308365855 hasAuthorship W4308365855A5033614042 @default.
• W4308365855 hasAuthorship W4308365855A5033776705 @default.
• W4308365855 hasAuthorship W4308365855A5039432822 @default.
• W4308365855 hasAuthorship W4308365855A5041339585 @default.
• W4308365855 hasAuthorship W4308365855A5046030309 @default.
• W4308365855 hasAuthorship W4308365855A5050920163 @default.
• W4308365855 hasAuthorship W4308365855A5060181316 @default.
• W4308365855 hasAuthorship W4308365855A5067237537 @default.
• W4308365855 hasAuthorship W4308365855A5070387023 @default.
• W4308365855 hasAuthorship W4308365855A5071880870 @default.
• W4308365855 hasAuthorship W4308365855A5071917576 @default.
• W4308365855 hasAuthorship W4308365855A5074500725 @default.
• W4308365855 hasAuthorship W4308365855A5081775695 @default.
• W4308365855 hasAuthorship W4308365855A5085683611 @default.
• W4308365855 hasBestOaLocation W43083658551 @default.
• W4308365855 hasConcept C119060515 @default.
• W4308365855 hasConcept C126322002 @default.
• W4308365855 hasConcept C127413603 @default.
• W4308365855 hasConcept C141071460 @default.
• W4308365855 hasConcept C164705383 @default.
• W4308365855 hasConcept C168563851 @default.
• W4308365855 hasConcept C207103383 @default.
• W4308365855 hasConcept C2776301958 @default.
• W4308365855 hasConcept C2778063415 @default.
• W4308365855 hasConcept C2778653478 @default.
• W4308365855 hasConcept C2778661090 @default.
• W4308365855 hasConcept C2779161974 @default.
• W4308365855 hasConcept C2780638905 @default.
• W4308365855 hasConcept C2780645631 @default.
• W4308365855 hasConcept C3019040382 @default.
• W4308365855 hasConcept C44249647 @default.
• W4308365855 hasConcept C71924100 @default.

• next